Foment Bio
About this raise
Foment Bio, with a valuation of $17.5 million, is raising funds on StartEngine. It is a biopharmaceutical company developing a novel transient gene therapy platform to treat cardiometabolic dysfunction. Foment Bio’s transient gene therapy leads to regenerative exosome production inside the body and prevents cell death, reduces fibrosis, decreases inflammation, and restores microvasculature. The platform has high potential in human indications, but its development in the companion animal space offers a higher potential for near-term commercialization. Ben Chlebina and Marc Penn founded Foment Bio in February 2023. The current crowdfunding campaign has a minimum target of $124,000 and a maximum target of $1.24 million. The campaign proceeds will be used for legal and IP maintenance, research and development, manufacturing and inventory, and personnel expenses.
Investment Overview
Committed $20,700 :
Deal Terms
Company & Team
Company
- Year Founded
- 2023
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B2C
- Margin
- Medium
- Capital Intensity
- High
Financials
-
Revenue
-
$0
as of FY2024
- Monthly Burn
-
$35,000
as of Mar '25
-
Runway
-
0.2 months
as of Mar '25
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
- Total Prior Capital Raised
- $542,550
- VC Backed?
- No
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
07/22/2025 | StartEngine | $17,500,000 | $20,700 | SAFE | Active | RegCF |